Of major significance in these ovarian cancer patients, there was clear evidence for amplification of T cell responses against known ovarian tumor antigens after intraperitoneal MV-NIS administration, even though all patients were measles-immune pretherapy. This evidence concerns the gene SLC5A5 and ovarian carcinoma.